Pharmacoeconomic analysis of leuprolide acetate (Eligard) 45 mg once in 6 months for advanced prostate cancer in Russian Federation
https://doi.org/10.17650/1726-9776-2015-11-4-65-71
Abstract
Objective – to conduct pharmacoeconomic study of leuprolide acetate 45 mg once in 6 months (Eligard) for advanced prostate cancer from the perspective of Russian health care system
Materials and methods. Cost minimization analysis (CMA) and budget impact analysis (BIA) were performed. All calculations were made in the MS Excel model. CMA compared leuprolide acetate once in 6 months (Eligard 45 mg) with 7 other prolonged gonadotropin-releasing hormone (GnRH) analogs. BIA compared two scenarios: common practice consisting of 4 GnRH analogs; new practice that is leuprolide acetate once in 6 months in 20 % of patients. Costs of drugs, visits to oncologist and injections were calculated both in CMA and BIA. Time horizon was 5 years for CMA and 3 years for BIA. Number of patients treated with GnRH was defined taking into account 5 year survival rate. One-way sensitivity analysis was performed.
Results. Leuprolide acetate (Eligard) 45 mg is the most cost-saving option among all compared. Sensitivity analysis demonstrated that the results are sustainable if input parameters are varied in the range ± 25 % from baseline. Budget economy is expected when Eligard 45 mg is used in a part of patients population instead of other prolonged GnRH analogs.
About the Authors
M. Yu. Frolov
Volgograd State Medical University
Russian Federation
1 Pavshikh Bortsov Square, Volgograd, 400131
Russian Federation
1 Pavshikh Bortsov Square, Volgograd, 400131
M. V. Avksentyeva
Russian Presidential Academy of National Economy and Public Administration;
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Build. 1, 82 prospect Vernadskogo, Moscow, 119571;
Build. 2, 8 Trubetskaya St., Moscow, 119992
References
1. Злокачественные новообразования в России в 2013 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.,2015. 250 с. [Malignant neoplasms in Russia in 2013 (morbidity and mortality rate). Ed. by A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Мoscow, 2015. 250 p. (In Russ.)].
2. Состояние онкологической помощи населению России в 2013 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России, 2014. 235 с. [Status of cancer care for people of Russia in 2013. Ed. by A.D. Kaprin, V.V. Starinsky, G.V. Petrova. Moscow: FSBE “P.A. Hertzen Moscow Cancer Research Institute” of the Ministry of Health of Russia, 2014. 235 p. (In Russ.)].
3. Клинические протоколы диагностики и лечения злокачественных новообразований (проект). Ассоциация онкологов России. Москва, 2012. Электронный документ. URL: http://www.oncology.ru/specialist/journal_oncology/archive/0512/001/038.pdf. [Clinical trials for diagnosis and treatment of malignant tumors (project). Association of Russian oncologists. Moscow, 2012. Electronic document. URL: http://www.oncology.ru/specialist/journal_oncology/archive/0512/001/038.pdf (In Russ.)].
4. Cox M.C., Scripture C.D., Figg W.D. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain? Expert Rev Anticancer Ther 2005;5:605–611.
5. Mcleod D.G. Hormonal therapy: historical perspective to future directions. Urology 2003;61(2 Suppl 1):3–7.
6. Schulman C. Assessing the attitudes to prostate cancer treatment among European male patients. BJU Int 2007;100(Suppl 1): 6–11.
7. Montorsi F., Tomlinson P. Which luteinising hormone-releasing hormone agonist injection schedule do men with prostate cancer prefer? Results of a European patient survey. European urology 2014;67(1):177–9.
8. Seidenfeld J., Samson D.J., Hasselblad V. et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132(7):566–77.
9. Dias Silva É., Ferreira U., Matheus W. et al. Goserelin versus leuprolide in the chemical castration of patients with prostate cancer. Int Urol Nephrol 2012;44(4):1039–44.
10. Fujii Y., Yonese J., Kawakami S. et al. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer. BJU Int 2008;101(9): 1096–100.
11. Sethi R., Sanfilippo N. Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer. Clinical interventions in aging 2009;4:259–67.
12. Herranz Amo F. Comparative analysis of six months formulation of LHRH analogues for prostate cancer treatment. Arch Esp Urol 2010;63(4):275–81.
13. Омельяновский В.В., Авксентьева М.В., Крысанов И.С. и др. Сравнительная клинико-экономическая оценка гормонотерапии рака предстательной железы с использованием аналогов гонадотропин-рилизинг-гормона (лейпрорелина, гозерелина, трипторелина). Медицинские технологии. Оценка и выбор 2012;4(10):52–8. [Omelyanovsky V.V, Avksentyeva M.V., Krysanov I.S. et al. Comparative clinical and economic evaluation of prostate cancer hormone therapy with gonadotropin-releasing hormone analogues (leuprorelin, goserelin, triptorelin). Medical technologies. Assessment and choice 2012;4(10):52–8. (In Russ.)].
14. Sullivan S.D., Mauskopf J.A., Augustovski F. et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health 2014;17(1):5–14.
15. Wex J., Sidhu M., Odeyemi I. Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation. ClinicoEconomics and Outcomes Research 2013;5:257–69.
16. Odeyemi I.A., Berges R., Bolodeoku J. Economic impact of different preparations of leuprolide acetate in the management of advanced prostate cancer. J Med Econom 2007;10(2):135–46.
17. Iannazzo S., Pradelli L., Carsi M., Perachino M. Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy. Value in Health 2011;14(1):80–9.
18. Tundia N., Fuldeore M., Gruca D. et al. Cost effectiveness of treatment with new 6-month leoprorelin acetate formulation in patients with advanced prostate cancer. Paper presented at: ISPOR 15th Annual European Congress 2012; Berlin, Germany
Review
For citations:
Frolov M.Yu., Avksentyeva M.V. Pharmacoeconomic analysis of leuprolide acetate (Eligard) 45 mg once in 6 months for advanced prostate cancer in Russian Federation. Cancer Urology. 2015;11(4):65-71. (In Russ.) https://doi.org/10.17650/1726-9776-2015-11-4-65-71
Views:
2124
Email this article 